T-lymphocytes and disease mechanisms in Wegener's granulomatosis

Kidney and Blood Pressure Research

Volumn 32, Issue 6, 2010, Pages 389-398

  Hua, Fan ^a   Wilde, Benjamin ^a   Dolff, Sebastian ^a   Witzke, Oliver ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Anti neutrophil cytoplasmic antibodies; Regulatory T cells; T cells; Vasculitis; Wegener's granulomatosis

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; CHEMOKINE; CORTICOSTEROID; CYTOKINE; ETANERCEPT; INFLIXIMAB; MYELOBLASTIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; PLACEBO; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR;

CELL POLARITY; CELL POPULATION; CLINICAL TRIAL; GENOTYPE; GRANULOMA; GRANULOMATOUS INFLAMMATION; HUMAN; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS AUREUS; T LYMPHOCYTE; VASCULITIS; WEGENER GRANULOMATOSIS;

CHEMOKINES; CYTOKINES; GENOTYPE; GRANULOMA; HUMANS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; WEGENER GRANULOMATOSIS;

EID: 70449513451     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000256409     Document Type: Review

References (96)

1. Bosch X, Guilabert A, Font J: Antineutrophil cytoplasmic antibodies. Lancet 2006; 368: 404-418.
2. Eisenberger U, Fakhouri F, Vanhille P, Beaufils H, Mahr A, Guillevin L, et al: ANCA-negative pauci-immune renal vasculitis: histology and outcome. Nephrol Dial Transplant 2005;20:1392-1399.
3. Reinhold-Keller E, de Groot K, Holl-Ulrich K, Arlt AC, Heller M, Feller AC, et al: Severe CNS manifestations as the clinical hallmark in generalized Wegener's granulomatosis consistently negative for antineutrophil cytoplasmic antibodies. A report of 3 cases and a review of the literature. Clin Exp Rheumatol 2001;19:541-549.
4. Scott DGI, Watts RA: Systemic vasculitis: epidemiology, classification and environmental factors. Ann Rheum Dis 2000; 59: 161-163.
5. Kallenberg CGM: Pathogenesis of PR3-ANCA-associated vasculitis. J Autoimmun 2008;30:29-36.
6. Xiao H, Heeringa P, Hu PQ, Liu Z, Zhao ML, Aratani Y, et al: Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110:955-963.
7. Ruth AJ, Kitching AR, Kwan RYQ, Odobasic D, Ooi JDK, Timoshanko JR, et al: Anti-neutrophil cytoplasmic antibodies and effector CD4+ cells play nonredundant roles in antimyeloperoxidase crescentic glomerulonephritis. J Am Soc Nephrol 2006; 17:1940-1949.
8. Brouwer E, Huitema MG, Klok PA, de Weerd H, Tervaert JW, Weening JJ, et al: Antimy-eloperoxidase-associated proliferative glomerulonephritis: an animal model. J Exp Med 1993;177:905-914.
9. Pfister H, Ollert M, Frohlich LF, Quintanilla-Martinez L, Colby TV, Specks U, et al: Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood 2004;104:1411-1418.
10. Segelmark M, Phillips BD, Hogan SL, Falk RJ, Jennette JC: Monitoring proteinase 3 antineutrophil cytoplasmic antibodies for detection of relapses in small vessel vasculitis. Clin Vaccine Immunol 2003;10:769-774.
11. Cohen Tervaert JW, Huitema MG, Sluiter WJ, The TH, van der Hem GK, Kallenberg CGM, et al: Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990;336:709-711.
12. Boomsma MM, Stegeman CA, van der Leij MJ, Oost W, Hermans J, Kallenberg CGM, et al: Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels - a prospective study. Arthritis Rheum 2000;43:2025-2033.
13. Finkielman JD, Merkel PA, Schroeder D, Hoffman GS, Spiera R, St. Clair EW, et al: Antiproteinase-3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 2007; 147:611-619.
14. Rarok AA, Stegeman CA, Limburg PC, Kallenberg CGM: Neutrophil membrane expression of proteinase 3 (PR3) is related to relapse in PR3-ANCA-associated vasculitis. J Am Soc Nephrol 2002; 13:2232-2238.
15. Taylor SRJ, Salama AD, Joshi L, Pusey CD, Lightman SL: Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum 2009; 60:1540-1547.
16. Brouwer E, Tervaert JWC, Horst G, Huitema MG, Vandergiessen M, Limburg PC, et al: Predominance of IgG1 and IgG4 subclasses of antineutrophil cytoplasmic autoantibodies in patients with Wegener's granulomatosis and clinically related disorders. Clin Exp Immunol 1991;83:379-386.
17. Voswinkel J, Muller A, Lamprecht P: Is PR3-ANCA formation initiated in Wegener's granulomatosis lesions? Granulomas as potential lymphoid tissue maintaining autoantibody production. Ann NY Acad Sci 2005; 1051:12-19.
18. Voswinkel J, Mueller A, Kraemer JA, Lamprecht P, Herlyn K, Holl-Ulrich K, et al: B-lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions. Ann Rheum Dis 2006;65:859-864.
19. Co DO, Hogan LH, Il-Kim S, Sandor M: T cell contributions to the different phases of granuloma formation. Immunol Lett 2004; 92:135-142.
20. Sato IY, Kobayashi K, Yamagata N, Shikama Y, Kasama T, Kasahara K, et al: Modulation of granuloma formation in vitro by endogenous mediators. Immunopharmacology 1991;21:73-82.
21. Aries PM, Lamprecht P, Gross WL: Wegener's granulomatosis: a view from the granulomatous side of the disease. Isr Med Assoc J 2005;7:768-773.
22. Schmitt WH, Heesen C, Csernok E, Rautmann A, Gross WL: Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Association with disease activity. Arthritis Rheum 1992; 35:1088-1096.
23. Abdulahad WH, van der Geld YM, Stegeman CA, Kallenberg CG: Persistent expansion of CD4+ effector memory T cells in Wegener's granulomatosis. Kidney Int 2006;70: 938-947.
24. Fienberg R: A morphologic and immunohistologic study of the evolution of the necrotizing palisading granuloma of pathergic (Wegener's) granulomatosis. Semin Respir Med 1989;10:126-132.
25. Lamprecht P, Moosig F, Csernok E, Seitzer U, Schnabel A, Mueller A, et al: CD28 negative T cells are enriched in granulomatous lesions of the respiratory tract in Wegener's granulomatosis. Thorax 2001;56:751-757.
26. Lamprecht P, Mueller A, Gross WL: CD28-T cells display features of effector memory T cells in Wegener's granulomatosis. Kidney Int 2004;65:1113-1114.
27. Moosig F, Csernok E, Wang G, Gross WL: Costimulatory molecules in Wegener's granulomatosis: lack of expression of CD28 and preferential up-regulation of its ligands B7-1 (CD80) and B7-2 (CD86) on T cells. Clin Exp Immunol 1998;114:113-118.
28. Steiner K, Moosig F, Csernok E, Selleng K, Gross WL, Fleischer B, et al: Increased expression of CTLA-4 (CD152) by T and B lymphocytes in Wegener's granulomatosis. Clin Exp Immunol 2001; 126:143-150.
29. 3 kinase function. J Exp Med 2004;199:831-842.
30. Komocsi A, Lamprecht P, Csernok E, Mueller A, Holl-Ulrich K, Seitzer U, et al: Peripheral blood and granuloma CD4+CD28-T cells are a major source of interferon-γ and tumor necrosis factor-α in Wegener's granulomatosis. Am J Pathol 2002;160:1717-1724.
31. Csernok E, Ai M, Gross WL, Wicklein D, Petersen A, Lindner B, et al: Wegener autoantigen induces maturation of dendritic cells and licenses them for Thl priming via the protease-activated receptor-2 pathway. Blood 2006;107:4440-4448.
32. Spriewald BM, Witzke O, Wassmuth R, Wenzel RR, Arnold ML, Philipp T, et al: Distinct tumour necrosis factor-α, interferon-γ, interleukin-10, and cytotoxic T-cell antigen 4 gene polymorphisms in disease occurrence and end-stage renal disease in Wegener's granulomatosis. Ann Rheum Dis 2005;64: 457-461.
33. Zhou YH, Huang DR, Paris PL, Sauter CS, Prock KA, Hoffman GS: An analysis of CTLA-4 and proinflammatory cytokine genes in Wegener's granulomatosis. Arthritis Rheum 2004;50:2645-2650.
34. Huang DR, Giscombe R, Zhou YH, Pirskanen R, Lefvert AK: Dinucleotide repeat expansion in the CTLA-4 gene leads to T cell hyperreactivity via the CD28 pathway in myasthenia gravis. J Neuroimmunol 2000; 105:69-77.
35. Ueda H, Howson JMM, Esposito L, Heward J, Snook H, Chamberlain G, et al: Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003;423:506-511.
36. Jagiello P, Aries P, Arning L, Wagenleiter SEN, Csernok E, Heimlich B, et al: The PTPN22 620W allele is a risk factor for Wegener's granulomatosis. Arthritis Rheum 2005;52:4039-4043.
37. Mustelin T, Alonso A, Bottini N, Huynh H, Rahmouni S, Nika K, et al: Protein tyrosine phosphatases in T-cell physiology. Mol Immunol 2004;41:687-700.
38. Luzina IG, Atamas SP, Starrer CE, daSilva LC, Kelsoe G, Papadimitriou JC, et al: Spontaneous formation of germinal centers in autoimmune mice. J Leukoc Biol 2001;70:578-584.
39. Hasegawa K, Martin F, Huang GM, Tumas D, Diehl L, Chan AC: PEST domain-enriched tyrosine phosphatase (PEP) regulation of effector/memory T cells. Science 2004;303:685-689.
40. Huang D, Giscombe R, Zhou YH, Lefvert K: Polymorphisms in CTLA-4 but not tumor necrosis factor-α or interleukin-1β genes are associated with Wegener's granulomatosis. J Rheumatol 2000;27:397-401.
41. Murakozy G, Gaede KI, Ruprecht B, Gutzeit O, Schurmann M, Schnabel A, et al: Gene polymorphisms of immunoregulatory cytokines and angiotensin-converting enzyme in Wegener's granulomatosis. J Mol Med 2001;79:665-670.
42. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV: An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997;24:1-8.
43. Scheffold A, Hühn J, Höfer T: Regulation of CD4+CD25+ regulatory T cell activity: it takes (IL-)two to tango. Eur J Immunol 2005; 35:1336.
44. Wraith DC, Nicolson KS, Whitely NT: Regulatory CD4+ T cells and the control of autoimmune disease. Curr Opin Immunol 2004; 16:695.
45. Chai JG, Xue SA, Coe D, Addey C, Bartok I: Regulatory T cells, derived from naive CD4+CD25-T cells by in vitro FoxP3 gene transfer, can induce transplantation tolerance. Transplantation 2005;79:1310.
46. Fontenot JD, Rudensky AY: A well-adapted regulatory contrivance: regulatory T-cell development and the forkhead family transcription factor FoxP3. Nat Immunol 2005;6: 331.
47. Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL: X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001;27:18.
48. Marinaki S, Neumann I, Kalsch AI, Grimminger P, Breedijk A, Birck R, et al: Abnormalities of CD4 T-cell subpopulations in ANCA-associated vasculitis. Clin Exp Immunol 2005;140:181-191.
49. Abdulahad WH, Stegeman CA, van der Geld YM, Doornbos-van der Meer B, Limburg PC, Kallenberg CG: Functional defect of circulating regulatory CD4+ T cells in patients with Wegener's granulomatosis in remission. Arthritis Rheum 2007;56:2080-2091.
50. Ziegler SF: FoxP3: not just for regulatory T cells anymore. Eur J Immunol 2007;37:21-23.
51. Piccirillo CA: Regulatory T cells in health and disease. Cytokine 2008;43:395-401.
52. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK: Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006; 212:28-50.
53. Appay V, van Lier RAW, Sallusto F, Roederer M: Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A 2008;73A:975-983.
54. Vogt S, Iking-Konert C, Hug F, Andrassy K, Hansch GM: Shortening of telomeres: Evidence for replicative senescence of T cells derived from patients with Wegener's granulomatosis. Kidney Int 2003;63:2144-2151.
55. Marinaki S, Kalsch AI, Grimminger P, Breedijk A, Birck R, Schmitt WH, et al: Persistent T-cell activation and clinical correlations in patients with ANCA-associated systemic vasculitis. Nephrol Dial Transplant 2006;21:1825-1832.
56. Huddleston CA, Weinberg AD, Parker DC: OX40 (CD134) engagement drives differentiation of CD4+ T cells to effector cells. Eur J Immunol 2006;36:1093-1103.
57. Lathrop SK, Huddleston CA, Dullforce PA, Montfort MJ, Weinberg AD, Parker DC: A signal through OX40 (CD134) allows anergic, autoreactive T cells to acquire effector cell functions. J Immunol 2004; 172:6735-6743.
58. Valzasina B, Guiducci C, Dislich H, Killeen N, Weinberg AD, Colombo MP: Triggering of OX40 (CD134) on CD4+CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 2005;105:2845-2851.
59. Wilde B, Dolff S, Cai X, Specker C, Becker J, Totsch M, et al: CD4+CD25+ T-cell populations expressing CD134 and GITR are associated with disease activity in patients with Wegener's granulomatosis. Nephrol Dial Transplant 2009;24:161-171.
60. Balding CEJ, Howie AJ, Drake-Lee AB, Savage COS: Th2 dominance in nasal mucosa in patients with Wegener's granulomatosis. Clin Exp Immunol 2001; 125:332-339.
61. Csernok E, Trabandt A, Muller A, Wang GCC, Moosig F, Paulsen J, et al: Cytokine profiles in Wegener's granulomatosis - predominance of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum 1999;42:742-750.
62. Sanders JS, Stegeman CA, Kallenberg CG: The Th1 and Th2 paradigm in ANCA-associated vasculitis. Kidney Blood Press Res 2003;26:215-220.
63. Schonermarck U, Csernok E, Trabandt A, Hansen H, Gross WL: Circulating cytokines and soluble CD23, CD26 and CD30 in ANCA-associated vasculitides. Clin Exp Rheumatol 2000; 18:457-463.
64. Lamprecht P, Bruhl H, Erdmann A, Holl-Ulrich K, Csernok E, Seitzer U, et al: Differences in CCR5 expression on peripheral blood CD4+CD28-T cells and in granulomatous lesions between localized and generalized Wegener's granulomatosis. Clin Immunol 2003;108:1-7.
65. Muller A, Trabandt A, Gloeckner-Hofmann K, Seitzer U, Csernok E, Schonermarck U, et al: Localized Wegener's granulomatosis: predominance of CD26 and IFN-γ expression. J Pathol 2000;192:113-120.
66. Kurts C: Th17 cells: a third subset of CD4+ T effector cells involved in organ-specific autoimmunity. Nephrol Dial Transplant 2008; 23:816-819.
67. Korn T, Oukka M, Kuchroo V, Bettelli E: Th17 cells: effector T cells with inflammatory properties. Semin Immunol 2007; 19: 362-371.
68. Bettelli E, Oukka M, Kuchroo VK: Th-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007;8:345-350.
69. Hsu HC, Yang P, Wang J, Wu Q, Myers R, Chen J, et al: Interleukin-17-producing T-helper cells and interleukin-17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol 2008;9:166-175.
70. Hoshino H, Laan M, Sjöstrand M, Lötvall J, Skoogh B-E, Lindén A: Increased elastase and myeloperoxidase activity associated with neutrophil recruitment by IL-17 in airways in vivo. J Allergy Clin Immunol 2000; 105:143-149.
71. Abdulahad WH, Stegeman CA, Limburg PC, Kallenberg CG: Skewed distribution of Th17 lymphocytes in patients with Wegener's granulomatosis in remission. Arthritis Rheum 2008;58:2196-2205.
72. Popa ER, Stegeman CA, Abdulahad WH, van der Meer B, Arends J, Manson WM, et al: Staphylococcal toxic shock syndrome toxin-1 as a risk factor for disease relapse in Wegener's granulomatosis. Rheumatology 2007;46: 1029-1033.
73. Stegeman CA, Tervaert JWC, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CGM: Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994;120:12-17.
74. Stegeman CA, Cohen Tervaert JW, de Jong PE, Kallenberg CGM, The Dutch Co-trimoxazole Wegener Study G: Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. N Engl J Med 1996;335:16-20.
75. Pendergraft WF, Preston GA, Shah RR, Tropsha A, Carter CW, Jennette JC, et al: Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat Med 2004;10:72-79.
76. McGuire KL, Holmes DS: Role of complementary proteins in autoimmunity: an old idea re-emerges with new twists. Trends Immunol 2005;26:367-372.
77. Kain R, Exner M, Brandes R, Ziebermayr R, Cunningham D, Alderson CA, et al: Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med 2008; 14: 1088-1096.
78. Popa ER, Stegeman CA, Bos NA, Kallenberg CGM, Tervaert JWC: Staphylococcal super-antigens and T-cell expansions in Wegener's granulomatosis. Clin Exp Immunol 2003; 132:496-504.
79. Muller-Alouf H, Carnoy C, Simonet M, Alouf JE: Superantigen bacterial toxins: state of the art. Toxicon 2001;39:1691-1701.
80. Schmitt WH, Hagen EC, Neumann I, Nowack R, Flores-Suarez LF, van der Woude FJ: Treatment of refractory Wegener's granulomatosis with anti-thymocyte globulin: An open study in 15 patients. Kidney Int 2004; 65:1440-1448.
81. Hagen EC, Dekeizer RJW, Andrassy K, Vanboven WPL, Bruijn JA, Vanes LA, et al: Compassionate treatment of Wegener's granulomatosis with rabbit anti-thymocyte globulin. Clin Nephrol 1995;43:351-359.
82. Tarkowski A, Anderssongare B, Aurell M: Use of anti-thymocyte globulin in the management of refractory systemic autoimmune diseases. Scand J Rheumatol 1993;22:261-266.
83. Wertheim MS, Ross AH, Tole DM: The use of Campath in severe peripheral ulcerative keratitis associated with Wegener's granulomatosis. Eye 2006;20:1453-1454.
84. Lockwood CM: Refractory Wegener's granulomatosis: a model for shorter immunotherapy of autoimmune diseases. J R Coll Physicians Lond 1998;32:473-478.
85. Lockwood CM, Thiru S, Isaacs JD, Hale G, Waldmann H: Long-term remission of intractable systemic vasculitis with monoclonal-antibody therapy. Lancet 1993; 341: 1620-1622.
86. Mathieson PW, Cobbold SP, Hale G, Clark MR, Oliveira DBG, Lockwood CM, et al: Monoclonal-antibody therapy in systemic vasculitis. N Engl J Med 1990;323:250-254.
87. Stone JH, Hoffman GS, Holbrook JT, Mein-ert CL, Dodge J, Donithan J, et al: Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352:351-361.
88. Stone JH, Holbrook JT, Marriott MA, Tibbs AK, Sejismundo LP, Min YI, et al: Solid malignancies among patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum 2006;54:1608-1618.
89. Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, Le Hello C, et al: Efficacy of the anti-TNF-α antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology 2002;41: 1126-1132.
90. Lamprecht P, Voswinkel J, Lilienthal T, Nolle B, Heller M, Gross WL, et al: Effectiveness of TNF-α blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology 2002;41:1303-1307.
91. Huugen D, Tervaert JWC, Heeringa P: TNF-α bioactivity-inhibiting therapy in ANCA-associated vasculitis: clinical and experimental considerations. Clin J Am Soc Nephrol 2006;1:1100-1107.
92. Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J, et al: Prospective study of TNF-α blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004; 15:717-721.
93. Vincenti F, Luggen M: T-cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation. Annu Rev Med 2007; 58: 347-358.
94. Cunnane G, Chan OTM, Cassafer G, Brindis S, Kaufman E, Yen TSB, et al: Prevention of renal damage in murine lupus nephritis by CTLA-4Ig and cyclophosphamide. Arthritis Rheum 2004;50:1539-1548.
95. Levine SM, Stone JH: New approaches to treatment in systemic vasculitis: biological therapies. Best Pract Res Clin Rheumatol 2001;15:315-333.
96. Hoff H, Knieke K, Cabail Z, Hirseland H, Vratsanos G, Burmester GR, et al: Surface CD152 (CTLA-4) expression and signaling dictates longevity of CD28null T cells. J Immunol 2009;182:5342-5351.